Details of the Drug

General Information of Drug (ID: DM7RJXL)

• Drug Name: Imatinib
• Synonyms: Cgp 57148; Glamox; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib (STI571); Imatinib Methansulfonate; Imatinib [INN:BAN]; 112GI019; 152459-95-5; BKJ8M8G5HI; CCRIS 9076; CGP-57148; CHEMBL941; Imatinib free base; STI; UNII-BKJ8M8G5HI

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive	N.A.	Approved	[2]
Choroidal neovascularization	9B76	Approved	[2]
Chronic eosinophilic leukemia	N.A.	Approved	[2]
Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Chronic myeloid leukaemia	2A20	Approved	[4]
Dermatofibrosarcoma protuberans	N.A.	Approved	[2]
Gastrointestinal stromal tumour	2B5B	Approved	[2]
Leukemia	N.A.	Approved	[2]
Malignant peripheral nerve sheath tumor	N.A.	Approved	[2]
Myeloproliferative neoplasm	2A20	Approved	[2]
Pulmonary hypertension	BB01	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[5]
Intestinal cancer	2C0Z	Phase 3	[3]
Lung cancer	2C25.0	Phase 2	[3]
Idiopathic hypereosinophilic syndrome	N.A.	Investigative	[2]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[6]
Scleroderma	4A42	Investigative	[2]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[6]
Systemic mastocytosis	2A21.0	Investigative	[7]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 493.6
  Logarithm of the Partition Coefficient (xlogp); 3.5
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [8]
  Bioavailability: 98% of drug becomes completely available to its intended biological destination(s) [9]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 3.3 mL/min/kg [10]
  Elimination: 5% of drug is excreted from urine in the unchanged form [8]
  Half-life: The concentration or amount of drug in body reduced by one-half in 22 hours [10]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.25863 micromolar/kg/day [11]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.05% [10]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [10]
  Water Solubility: The ability of drug to dissolve in water is measured as 1 mg/mL [8]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Chronic myeloid leukaemia	Not Available	LEP	OT5Q7ODW	[12]

• Chemical Identifiers:
  Formula: C29H31N7O
  IUPAC Name: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
  Canonical SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
  InChI: InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
  InChIKey: KTUFNOKKBVMGRW-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5291
  ChEBI ID: CHEBI:45783
  CAS Number: 152459-95-5
  DrugBank ID: DB00619
  TTD ID: D0AZ3C
  VARIDT ID: DR00032
  INTEDE ID: DR0858
  ACDINA ID: D00324
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[13]
Mcl-1 messenger RNA (MCL-1 mRNA)	TTN6ORK	MCL1_HUMAN	Not Available	[7]
Platelet-derived growth factor receptor (PDGFR)	TTI2WET	NOUNIPROTAC	Inhibitor	[13]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[13]
HUMAN fusion protein Bcr-Abl (Bcr-Abl)	TTE63HY	BCR_HUMAN/ABL1_HUMAN	Inhibitor	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[14]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[15]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[16]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[17]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[17]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[18]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[19]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[20]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[21]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[22]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[23]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[24]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[25]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[20]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Protein Interaction/Cellular Processes	[26]
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Gene/Protein Processing	[27]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[28]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[28]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM)	OT1QY9JM	PFKAM_HUMAN	Gene/Protein Processing	[29]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[30]
Autophagy-related protein 13 (ATG13)	OTYMHNEJ	ATG13_HUMAN	Post-Translational Modifications	[31]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Drug Response	[32]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[33]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Drug Response	[34]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Imatinib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Imatinib caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[35]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Imatinib caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Imatinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Imatinib caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[38]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[39]

Coadministration of a Drug Treating the Disease Different from Imatinib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[40]
Tretinoin	DM49DUI	Moderate	Decreased metabolism of Imatinib caused by Tretinoin mediated inhibition of CYP450 enzyme.	Acne vulgaris [ED80]	[41]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Imatinib caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[42]
Repaglinide	DM5SXUV	Moderate	Decreased metabolism of Imatinib caused by Repaglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[43]
Pioglitazone	DMKJ485	Moderate	Decreased metabolism of Imatinib caused by Pioglitazone mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[35]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Imatinib caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[44]
Ivosidenib	DM8S6T7	Major	Increased metabolism of Imatinib caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[45]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Imatinib caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[46]
Arn-509	DMT81LZ	Major	Increased metabolism of Imatinib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[42]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Imatinib caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[37]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Imatinib caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[47]
Mitotane	DMU1GX0	Major	Increased metabolism of Imatinib caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[42]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Imatinib caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[48]
Ivabradine	DM0L594	Major	Decreased metabolism of Imatinib caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[37]
Bepridil	DM0RKS4	Moderate	Decreased metabolism of Imatinib caused by Bepridil mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[35]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Imatinib caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[49]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Imatinib caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[35]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[50]
Clorazepate	DMC3JST	Moderate	Decreased metabolism of Imatinib caused by Clorazepate mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[40]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Imatinib caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[42]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Imatinib caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[35]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Imatinib caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[51]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Roflumilast.	Asthma [CA23]	[37]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Imatinib caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[35]
Oritavancin	DM28D05	Moderate	Increased metabolism of Imatinib caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[42]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Imatinib caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Imatinib caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Imatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Imatinib caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[52]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[40]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Imatinib caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[53]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[54]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Imatinib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[55]
Ixabepilone	DM2OZ3G	Moderate	Decreased metabolism of Imatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[56]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Imatinib caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[57]
HKI-272	DM6QOVN	Major	Decreased metabolism of Imatinib caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[58]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Imatinib caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[59]
Esterified estrogens	DM9KZDO	Moderate	Decreased metabolism of Imatinib caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Imatinib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Tamoxifen	DMLB0EZ	Moderate	Decreased metabolism of Imatinib caused by Tamoxifen mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Imatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[60]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Imatinib caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Estradiol	DMUNTE3	Moderate	Decreased metabolism of Imatinib caused by Estradiol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Atorvastatin	DMF28YC	Moderate	Decreased metabolism of Imatinib caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[61]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Imatinib caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[62]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Imatinib caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[63]
Indacaterol	DMQJHR7	Minor	Decreased metabolism of Imatinib caused by Indacaterol mediated inhibition of CYP450 enzyme.	Chronic obstructive pulmonary disease [CA22]	[64]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Imatinib caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[42]
Dihydrocodeine	DMB0FWL	Moderate	Decreased metabolism of Imatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[40]
Irinotecan	DMP6SC2	Moderate	Decreased metabolism of Imatinib caused by Irinotecan mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[65]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Imatinib caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[37]
Mestranol	DMG3F94	Moderate	Decreased metabolism of Imatinib caused by Mestranol mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[40]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Imatinib caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[37]
Cocaine	DMSOX7I	Moderate	Decreased metabolism of Imatinib caused by Cocaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[40]
Alfentanil	DMVO0UB	Major	Decreased metabolism of Imatinib caused by Alfentanil mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[66]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Imatinib caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[67]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Imatinib caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[37]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Imatinib caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[37]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Imatinib caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[35]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Imatinib caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[40]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Imatinib caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[68]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Imatinib caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Trimipramine	DM1SC8M	Moderate	Decreased metabolism of Imatinib caused by Trimipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Imatinib caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[69]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Imatinib caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Escitalopram	DMFK9HG	Minor	Decreased metabolism of Imatinib caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Desvenlafaxine	DMHD4PE	Moderate	Decreased metabolism of Imatinib caused by Desvenlafaxine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
OPC-34712	DMHG57U	Major	Decreased metabolism of Imatinib caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[71]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Imatinib caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Trazodone	DMK1GBJ	Moderate	Decreased metabolism of Imatinib caused by Trazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Doxepin	DMPI98T	Moderate	Decreased metabolism of Imatinib caused by Doxepin mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[35]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Imatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[72]
[3H]estrone-3-sulphate	DMGPF0N	Moderate	Decreased metabolism of Imatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[40]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Imatinib caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[73]
Diazepam	DM08E9O	Moderate	Decreased metabolism of Imatinib caused by Diazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Zonisamide	DM0DTF7	Moderate	Decreased metabolism of Imatinib caused by Zonisamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Primidone	DM0WX6I	Major	Increased metabolism of Imatinib caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Imatinib caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Imatinib caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Imatinib caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Tiagabine	DMKSQG0	Moderate	Decreased metabolism of Imatinib caused by Tiagabine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Imatinib caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[37]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Imatinib caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Clonazepam	DMTO13J	Moderate	Decreased metabolism of Imatinib caused by Clonazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Lacosamide	DMVM6QR	Moderate	Decreased metabolism of Imatinib caused by Lacosamide mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Imatinib caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Imatinib caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Imatinib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Imatinib caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[37]
Nicardipine	DMCDYW7	Moderate	Decreased metabolism of Imatinib caused by Nicardipine mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[35]
Mefenamic acid	DMK7HFI	Moderate	Decreased metabolism of Imatinib caused by Mefenamic acid mediated inhibition of CYP450 enzyme.	Female pelvic pain [GA34]	[35]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Imatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[74]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Imatinib caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[75]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Imatinib caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[76]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Imatinib caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[77]
Tolterodine	DMSHPW8	Moderate	Decreased metabolism of Imatinib caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[78]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Imatinib caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Imatinib caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Imatinib caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[79]
Dexlansoprazole	DM1DBV5	Moderate	Decreased metabolism of Imatinib caused by Dexlansoprazole mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[80]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Imatinib caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[40]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Imatinib caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[37]
Colchicine	DM2POTE	Major	Decreased metabolism of Imatinib caused by Colchicine mediated inhibition of CYP450 enzyme.	Gout [FA25]	[81]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Imatinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[42]
Ergotamine	DMKR3C5	Moderate	Decreased metabolism of Imatinib caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[82]
Eplerenone	DMF0NQR	Major	Decreased metabolism of Imatinib caused by Eplerenone mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[83]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Imatinib caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[35]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Imatinib caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[35]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Imatinib caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[35]
Daclatasvir	DMSFK9V	Moderate	Decreased metabolism of Imatinib caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[40]
Rifampin	DMA8J1G	Major	Increased metabolism of Imatinib caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[42]
Rifapentine	DMCHV4I	Major	Increased metabolism of Imatinib caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[42]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[84]
MK-1439	DM215WE	Minor	Decreased metabolism of Imatinib caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[85]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Imatinib caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[86]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Imatinib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Efavirenz	DMC0GSJ	Moderate	Decreased metabolism of Imatinib caused by Efavirenz mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Imatinib caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[87]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Imatinib caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Imatinib caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[88]
Rilpivirine	DMJ0QOW	Moderate	Decreased metabolism of Imatinib caused by Rilpivirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Imatinib caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Imatinib caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[89]
Maraviroc	DMTL94F	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[90]
Simvastatin	DM30SGU	Moderate	Decreased metabolism of Imatinib caused by Simvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[61]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Imatinib caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[40]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Imatinib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[91]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Imatinib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[92]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Imatinib caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[40]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[65]
Losartan	DM72JXH	Moderate	Decreased metabolism of Imatinib caused by Losartan mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[35]
Nebivolol	DM7F1PA	Moderate	Decreased metabolism of Imatinib caused by Nebivolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[35]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Imatinib caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[65]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Imatinib caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[35]
Pindolol	DMD2NV7	Moderate	Decreased metabolism of Imatinib caused by Pindolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[35]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Imatinib caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[93]
Tolvaptan	DMIWFRL	Moderate	Decreased metabolism of Imatinib caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[94]
Fludrocortisone	DMUDIR8	Moderate	Decreased metabolism of Imatinib caused by Fludrocortisone mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[35]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Imatinib caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[37]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Imatinib caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[95]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Imatinib caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[96]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Imatinib caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[35]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Imatinib caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[97]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Imatinib caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[42]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Imatinib caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[98]
Flurazepam	DMAL4G0	Moderate	Decreased metabolism of Imatinib caused by Flurazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[35]
Triazolam	DMETYK5	Moderate	Decreased metabolism of Imatinib caused by Triazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[35]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Imatinib caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[99]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Imatinib caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[100]
Estazolam	DMZGXUM	Moderate	Decreased metabolism of Imatinib caused by Estazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[35]
Pemigatinib	DM819JF	Major	Decreased metabolism of Imatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[37]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Imatinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[42]
Testosterone	DM7HUNW	Moderate	Decreased metabolism of Imatinib caused by Testosterone mediated inhibition of CYP450 enzyme.	Low bone mass disorder [FB83]	[35]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Imatinib and Denosumab.	Low bone mass disorder [FB83]	[101]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Imatinib caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
Brigatinib	DM7W94S	Major	Decreased metabolism of Imatinib caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[40]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Imatinib and Porfimer Sodium.	Lung cancer [2C25]	[102]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Imatinib caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[103]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Imatinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[104]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Imatinib caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Imatinib caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[105]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Imatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[106]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[107]
Selpercatinib	DMZR15V	Major	Decreased metabolism of Imatinib caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Halofantrine	DMOMK1V	Major	Decreased metabolism of Imatinib caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[108]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Imatinib caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[40]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Imatinib caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[35]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[109]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Idelalisib.	Mature B-cell leukaemia [2A82]	[110]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Imatinib caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Imatinib caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[111]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Imatinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[112]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Clofarabine.	Mature B-cell lymphoma [2A85]	[113]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Imatinib caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[114]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Imatinib caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[42]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Imatinib caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[115]
LGX818	DMNQXV8	Major	Decreased metabolism of Imatinib caused by LGX818 mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[116]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Imatinib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[42]
Estrone	DM5T6US	Moderate	Decreased metabolism of Imatinib caused by Estrone mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[35]
Ethinyl estradiol	DMODJ40	Moderate	Decreased metabolism of Imatinib caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme.	Menopausal disorder [GA30]	[40]
Danazol	DML8KTN	Moderate	Decreased metabolism of Imatinib caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[35]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Imatinib caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[117]
Almogran	DM7I64Z	Moderate	Decreased metabolism of Imatinib caused by Almogran mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[35]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Imatinib caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[118]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[119]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Imatinib caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[120]
Flibanserin	DM70DTN	Major	Decreased metabolism of Imatinib caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[121]
Midazolam	DMXOELT	Moderate	Decreased metabolism of Imatinib caused by Midazolam mediated inhibition of CYP450 enzyme.	Mood/affect symptom [MB24]	[35]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Imatinib caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[122]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Tecfidera.	Multiple sclerosis [8A40]	[123]
Siponimod	DM2R86O	Major	Decreased metabolism of Imatinib caused by Siponimod mediated inhibition of CYP450 enzyme.	Multiple sclerosis [8A40]	[40]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Imatinib and Fingolimod.	Multiple sclerosis [8A40]	[124]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Ocrelizumab.	Multiple sclerosis [8A40]	[125]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Imatinib caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[37]
Modafinil	DMYILBE	Minor	Decreased metabolism of Imatinib caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[40]
Promethazine	DM6I5GR	Moderate	Decreased metabolism of Imatinib caused by Promethazine mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[35]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Imatinib caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[37]
Granisetron	DMIUW25	Moderate	Decreased metabolism of Imatinib caused by Granisetron mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[35]
Ondansetron	DMOTQ1I	Moderate	Decreased metabolism of Imatinib caused by Ondansetron mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[35]
Entrectinib	DMMPTLH	Major	Decreased metabolism of Imatinib caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[40]
Sibutramine	DMFJTDI	Minor	Decreased metabolism of Imatinib caused by Sibutramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[126]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Imatinib caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[35]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Imatinib caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[127]
S-297995	DM26IH8	Moderate	Decreased metabolism of Imatinib caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[37]
Naproxen	DMZ5RGV	Moderate	Decreased metabolism of Imatinib caused by Naproxen mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[35]
Olaparib	DM8QB1D	Major	Decreased metabolism of Imatinib caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[40]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Imatinib caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[35]
Ibuprofen	DM8VCBE	Moderate	Decreased metabolism of Imatinib caused by Ibuprofen mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[35]
Methamphetamine	DMPM4SK	Moderate	Decreased metabolism of Imatinib caused by Methamphetamine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[40]
Buprenorphine	DMPRI8G	Moderate	Decreased metabolism of Imatinib caused by Buprenorphine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[128]
Hydrocodone	DMQ2JO5	Major	Decreased metabolism of Imatinib caused by Hydrocodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[129]
Istradefylline	DM20VSK	Moderate	Decreased metabolism of Imatinib caused by Istradefylline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[35]
Pimavanserin	DMR7IVC	Moderate	Decreased metabolism of Imatinib caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[130]
Bromocriptine	DMVE3TK	Moderate	Decreased metabolism of Imatinib caused by Bromocriptine mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[35]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Imatinib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[131]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Imatinib caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[132]
Prednisone	DM2HG4X	Moderate	Decreased metabolism of Imatinib caused by Prednisone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[35]
Hydrocortisone	DMGEMB7	Moderate	Decreased metabolism of Imatinib caused by Hydrocortisone mediated inhibition of CYP450 enzyme.	Postoperative inflammation [1A00-CA43]	[35]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Imatinib caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[133]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Imatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[134]
Enzalutamide	DMGL19D	Major	Increased metabolism of Imatinib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[42]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[135]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Imatinib caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[136]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Imatinib caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[137]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Imatinib caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[138]
Levomepromazine	DMIKFEL	Moderate	Decreased metabolism of Imatinib caused by Levomepromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[35]
Fluphenazine	DMIT8LX	Moderate	Decreased metabolism of Imatinib caused by Fluphenazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[35]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Imatinib caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[37]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Imatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[139]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Canakinumab.	Rheumatoid arthritis [FA20]	[140]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Rilonacept.	Rheumatoid arthritis [FA20]	[140]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Imatinib caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[42]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Imatinib and Leflunomide.	Rheumatoid arthritis [FA20]	[92]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Imatinib caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[35]
Quetiapine	DM1N62C	Moderate	Decreased metabolism of Imatinib caused by Quetiapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[141]
Mesoridazine	DM2ZGAN	Moderate	Decreased metabolism of Imatinib caused by Mesoridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[35]
Thioridazine	DM35M8J	Major	Decreased metabolism of Imatinib caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[142]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Imatinib caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[143]
Perphenazine	DMA4MRX	Moderate	Decreased metabolism of Imatinib caused by Perphenazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[35]
Risperidone	DMN6DXL	Moderate	Decreased metabolism of Imatinib caused by Risperidone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[35]
Fentanyl	DM8WAHT	Major	Decreased metabolism of Imatinib caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[40]
Sufentanil	DMU7YEL	Moderate	Decreased metabolism of Imatinib caused by Sufentanil mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[35]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Imatinib when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[144]
Avanafil	DM75CXN	Major	Decreased metabolism of Imatinib caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[145]
Tadalafil	DMJZHT1	Moderate	Decreased metabolism of Imatinib caused by Tadalafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[146]
Vardenafil	DMTBGW8	Moderate	Decreased metabolism of Imatinib caused by Vardenafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[147]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Imatinib caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[35]
Tedizolid	DMG2SKR	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[37]
LDE225	DMM9F25	Major	Decreased metabolism of Imatinib caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[148]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Imatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[37]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Imatinib caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
Methylprednisolone	DM4BDON	Moderate	Decreased metabolism of Imatinib caused by Methylprednisolone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Ifosfamide	DMCT3I8	Moderate	Decreased metabolism of Imatinib caused by Ifosfamide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Docetaxel	DMDI269	Moderate	Decreased metabolism of Imatinib caused by Docetaxel mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[149]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[37]
Armodafinil	DMGB035	Minor	Decreased metabolism of Imatinib caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
LEE011	DMMX75K	Moderate	Decreased metabolism of Imatinib caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Etoposide	DMNH3PG	Moderate	Decreased metabolism of Imatinib caused by Etoposide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Prednisolone	DMQ8FR2	Moderate	Decreased metabolism of Imatinib caused by Prednisolone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Norethindrone	DMTY169	Moderate	Decreased metabolism of Imatinib caused by Norethindrone mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[40]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Imatinib caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[150]
Doxorubicin	DMVP5YE	Moderate	Decreased metabolism of Imatinib caused by Doxorubicin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[35]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Imatinib caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[37]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Imatinib and Naltrexone.	Substance abuse [6C40]	[151]
Warfarin	DMJYCVW	Major	Decreased metabolism of Imatinib caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[65]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Imatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[152]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Imatinib due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[153]
As-1670542	DMV05SW	Major	Decreased metabolism of Imatinib caused by As-1670542 mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[154]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Imatinib caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[37]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Imatinib caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[37]
Cabozantinib	DMIYDT4	Moderate	Decreased metabolism of Imatinib caused by Cabozantinib mediated inhibition of CYP450 enzyme.	Thyroid cancer [2D10]	[155]
Sirolimus	DMGW1ID	Moderate	Decreased metabolism of Imatinib caused by Sirolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[35]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Imatinib and Azathioprine.	Transplant rejection [NE84]	[40]
Tacrolimus	DMZ7XNQ	Moderate	Decreased metabolism of Imatinib caused by Tacrolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[35]
Tolbutamide	DM02AWV	Moderate	Decreased metabolism of Imatinib caused by Tolbutamide mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[35]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Imatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[37]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Imatinib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[42]
Astemizole	DM2HN6Q	Moderate	Decreased metabolism of Imatinib caused by Astemizole mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[35]
Triamcinolone	DM98IXF	Moderate	Decreased metabolism of Imatinib caused by Triamcinolone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[35]
Fluticasone	DMGCSVF	Moderate	Decreased metabolism of Imatinib caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[40]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Imatinib caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[35]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Imatinib caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[35]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Imatinib caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[35]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Imatinib and Ganciclovir.	Virus infection [1A24-1D9Z]	[40]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Imatinib and Valganciclovir.	Virus infection [1A24-1D9Z]	[40]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Imatinib 100 mg tablet	100 mg	Oral Tablet	Oral
Imatinib 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Imatinib FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687).
• [4] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
• [5] ClinicalTrials.gov (NCT04356495) Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). U.S. National Institutes of Health.
• [6] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [7] Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
• [8] BDDCS applied to over 900 drugs
• [9] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [10] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [11] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [12] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [13] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [14] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [15] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [16] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [17] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [18] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [19] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [20] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [21] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [22] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [23] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [24] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [25] Drug Interactions Flockhart Table
• [26] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [27] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [28] Saikosaponin D disrupts platelet-derived growth factor- receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. Chem Biol Interact. 2013 Oct 25;206(1):76-82. doi: 10.1016/j.cbi.2013.08.006. Epub 2013 Aug 28.
• [29] Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
• [30] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [31] Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
• [32] Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
• [33] The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol. 2001 Mar;59(3):453-61. doi: 10.1124/mol.59.3.453.
• [34] Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009 Jul;45(10):1877-89. doi: 10.1016/j.ejca.2009.04.005. Epub 2009 May 4.
• [35] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [36] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [38] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [39] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [40] Cerner Multum, Inc. "Australian Product Information.".
• [41] Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
• [42] Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
• [43] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
• [44] Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
• [45] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [46] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [47] Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
• [48] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [49] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [50] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [51] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
• [52] Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
• [53] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [54] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [55] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [56] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [57] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [58] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
• [59] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [60] Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
• [61] Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
• [62] Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [63] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [64] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [65] Canadian Pharmacists Association.
• [66] Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
• [67] Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
• [68] Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
• [69] Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
• [70] Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
• [71] Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [72] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [73] Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
• [74] Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
• [75] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [76] Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
• [77] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [78] Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
• [79] Dutreix C, Peng B, Mehring G, et al. "Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects." Cancer Chemother Pharmacol 54 (2004): 290-4. [PMID: 15138710]
• [80] Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M "Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes." Eur J Clin Pharmacol 57 (2001): 709-15. [PMID: 11829200]
• [81] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
• [82] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
• [83] Product Information. Inspra (eplerenone). Searle, Chicago, IL.
• [84] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [85] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [86] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [87] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [88] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [89] Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
• [90] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [91] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [92] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [93] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [94] Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [95] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [96] Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [97] Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
• [98] Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [99] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [100] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [101] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [102] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [103] Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [104] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [105] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [106] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [107] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [108] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [109] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [110] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [111] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [112] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [113] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [114] Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
• [115] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [116] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [117] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [118] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [119] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [120] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [121] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [122] Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
• [123] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [124] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [125] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [126] Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
• [127] Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
• [128] Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
• [129] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
• [130] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [131] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [132] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [133] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
• [134] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [135] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [136] Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
• [137] Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
• [138] Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
• [139] Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [140] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [141] DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
• [142] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
• [143] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [144] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [145] Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
• [146] Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
• [147] Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
• [148] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [149] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
• [150] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
• [151] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [152] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [153] Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]
• [154] Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
• [155] Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.